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Abstract Glutaredoxin (Grx) (12 kDa) is a hydrogen donor for 
ribonucleotide reductase and also a general GSH-disulfide reduc- 
tase of importance for redox regulation. To overexpress human 
glutaredoxin in Escherichiu cofi, a cDNA encoding human Grx 
was modified and cloned into the vector PET-3d and expressed 
in E. coli BL21(DE3) by IPTG induction. High-level expression 
of Grx was verified by GSH-disulfide oxidoreductase activity, 
SDS-PAGE and immunoblotting analysis. The recombinant 
human Grx in its reduced form was purified to homogenity with 
50% yield and exhibited the same dehydroascorbate reductase 
and hydrogen donor activity for ribonucleotide reductase (K,,, - 0.2 
PM) as the human placenta protein. Human Grx contains a total 
of 5 half-cystine residues including a non-conserved Cys’ residue 
and is easily oxidized to form dimers during storage. A Grx 
mutant Cys’ to Ser was generated by site-directed mutagenesis 
and the protein was purified to homogeneity. The mutant protein 
showed full activity and exhibited a much reduced tendency to 
form dimers compared with the wild type protein. Peptide se- 
quencing confirmed the mutation and removal of the N-terminal 
Met residue in both wild type and mutant proteins. Fluorescence 
spectra demonstrated only tyrosine fluorescence in human Grx 
with a peak at 310 nm which increased 20% upon reduction and 
decreased by addition of GSSG demonstrating that glutathione- 
containing disulfides are excellent substrates. 
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1. Introduction 
Glutaredoxin (Grx) is a small protein (M, = 12,000) contain- 
ing the active site -Cys-Pro-Tyr-Cys- which is conserved in such 
different organisms as E. coli, vaccinia virus, yeast, plants and 
mammalian cells [l-8]. Grx was originally discovered in E. coli 
and calf thymus as a GSH-dependent hydrogen donor for ribo- 
nucleotide reductase [9%12], an essential enzyme for DNA syn- 
thesis. Glutaredoxin has inherent glutathione-disulfide ox- 
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idoreductase activity in a coupled system with GSH, NADPH 
and glutathione reductase [ 121, catalyzing the reduction of low 
molecular weight disulfides as well as proteins. Grx has been 
proposed to exert a general thiol redox control of protein activ- 
ity by acting both as an effective protein disulfide reductase, 
similar to thioredoxin [13,14], and as a specific GSH-mixed 
disulfide reductase. 
Mammalian glutaredoxins from calf thymus, rabbit bone 
marrow, pig liver and human placenta contain two structural 
half-cystine residues in the C-terminal part of potential regula- 
tory role since their oxidation inactivates enzyme activity [5]. 
Those two cysteines are part of a group of amino acids con- 
served among the TGF-p family and animal glutaredoxins [ 151. 
Glutaredoxin also exhibits dehydroascorbate reductase activ- 
ity, suggesting a function to defend cells against oxidative stress 
V61. 
Glutaredoxin genes (grx) have been cloned from E. coli, yeast 
and pig [17-211. Grx from placenta was previously purified to 
homogeneity (12 kDa) and its amino acid sequence was deter- 
mined (105 residues) by peptide sequencing and a cDNA en- 
coding the protein was cloned and sequenced [8]. Human Grx 
contains one extra Cys residue (Cys’) apart form the two active 
site cysteines and the previously mentioned two conserved half- 
cystine residues; the human protein therefore particularly easy 
forms multimers by disulfide bridges upon oxidation. 
In this article we describe the high-level expression of human 
glutaredoxin in E. coli and purification and characterization of 
recombinant wild type and a Cys’ to Ser mutant protein. 
2. Materials and methods 
2.1. Materials 
Purified recombinant mouse ribonucleotide reductase was a kind gift 
of Prof. L. Thelander of the University of Umea (Sweden). Antibodies 
against human placenta glutaredoxin were generated in a goat (Padilla 
et al. to be published). All other chemicals and reagents were of analyt- 
ical grade. 
2.2. Methods 
2.2.1. Construction of human glutaredoxin expression vector. The 
entire cDNA encoding human glutaredoxin [8] was amplified by PCR 
from plasmid pGEM(grx) by using two mutagenic primers (5’-CAT- 
CGCCATGGCTCAAGA-3’ and 5’-TTCCCATGGGATCTGTGGT- 
3’; the underlined bases were the mutations relative to the original 
cDNA sequence) to introduce a NcoI site at the initiation codon region 
and a NcoI site after the stop codon region (bold letters). The amplified 
DNA was cloned in expression vector PET-3d [22] and E. coli strain 
BL2l(DE3) was transformed with PET-grx. 
2.2.2. Construction of a mutant (Cys’ to Ser) expression vector. 
The procedure was the same that we have described above but changing 
the mutagenic primer at the 5’ end. The new primer (5’-ATCGCCA- 
TGGCTCAAGAGTTTGTGAACA GCA-3’) has a mutation toztro- 
duce a NcoI site at its initiation c%on region (underlined base) and 
another one to change Cys’ to Ser (double underlined base). 
2.2.3. Expression and pur$cation of recombinant human glutare- 
doxin. Transformed E. coli BL2l(DE3) cells with PET-grx 
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Fig. 1. Complete nucleotide sequence and deduced amino acid sequence 
of the human glutaredoxin cDNA modified for the overexpression of 
the protein E. coli. The initiator Met and the two NcoI sites are bold 
type. The translation termination signal is indicated by (***). The 
internal primers used for sequencing are underlined. 
were cultured at 37°C in 4 1 of fresh Luria-Bertani medium with 50 
@ml of ampicillin and shaken until an A,,, of 0.5 was obtained. Then, 
IPTG was added to a final concentration of 0.5 mM and the culture 
was continuously shaken at 37°C for 3.5 h. The following steps were 
carried out at 4°C. Cells were harvested by centrifugation at 10,000 x g 
for 20 min and the pellet (10 g) was resuspended in 50 ml of 50 mM 
Tris-HCl pH 7.5, 1 mM EDTA and 1 mM PMSF. Lysozyme was added 
to a final concentration of 0.2 mg/ml with stirring for at least 30 min 
and the cells were disrupted by sonication for 20 min (60 s x 30 s 
intervals). Insoluble material was sedimented at 15,000 x g for 30 min. 
After centrifugation the supernatant fraction was placed in a fresh tube 
and streptomycin sulphate was added to 0.5% saturation to precipitate 
nucleic acid. The mixture was stirred for 1 h. The suspension was 
centrifuged for 30 min at 15,000 x g and the supernatant was fractiona- 
s 1 2 3 4 
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ted by using ammonium sulphate 40% and 85% saturation to precipi- 
tate protein. The pellet from 85% saturation was dissolved in 30 ml of 
buffer A (50 mM Tris-HCl pH 7.5, 1 mM EDTA and 0.1 mM DTT), 
and dialyzed against the same buffer. This preparation was preincu- 
bated with 2 mM DTT at 37°C for 15 min and loaded onto a DEAE- 
Sephacel column (12 x 3.5 cm) that had been equilibrated with buffer 
A. The recombinant Grx did not bind under those conditions. The 
flow-through fractions containing activity were concentrated by ammo- 
nium sulphate precipitation (85%) and the pellet was resuspended in 3.5 
ml of buffer B (10 mM sodium phosphate buffer pH 6.8, 0.1 mM 
EDTA). The sample was preincubated with 2 mM DTT at 37°C for 15 
min and applied to a Sephadex G-50 column (142 x 1.5 cm), equili- 
brated with buffer B. The active fractions were pooled (80 ml), concen- 
trated by Diaflo ultrafiltration to 20 ml, incubated with 10 mM HED 
at room temperature for 30 min and loaded onto a CM-Sepharose 
column (17 x 1.6 cm) equilibrated with buffer B. The recombinant 
human glutaredoxin was eluted with a 300 ml total volume linear 
gradient of 0.0-0.5 M NaCl in buffer B. The protein concentration was 
determined as described by Bradford [23] using a BSA standard curve. 
Expression and purification of recombinant human glutaredoxin mu- 
tant were the same that we have described previously for the wild type 
protein. 
2.2.4. Assay of enzymatic activities. Glutathione-disulfide oxidore- 
ductase activity was determined as described by Luthman and 
Holmgren with HED [12] or dehydroascorbate [16] as substrates. The 
activity of the recombinant human glutaredoxin with the heterologous 
mouse ribonucleotide reductase was determined as described by Luth- 
man and Holmgren [12]. The R2 subunit of ribonucleotide reductase 
was reactivated following the anaerobic procedure described by Mann 
et al. [24]. 
2.2.5. SDS-PAGE, immunoblotting analysis and isoelectric focus- 
ing. SDS-PAGE was performed on Pharmacia Phast System 
using phast gel homogeneous 20%. The separated proteins were electro- 
phoretically transferred to nitrocellulose membranes (0.45 Bum) and the 
blots were developed as described by Rozell et al., [25] using affinity- 
purified goat anti-human glutaredoxin as primary antibodies. Isoelec- 
tric focusing was performed on a Pharmacia Phast System using gels 
3-10 supplied by the manufacturer and silver staining. 
2.2.6. Fluorescence measurements.. Protein fluorescence was meas- 
ured with a thermostated SPEX-FluoroMax spectrofluorometer at 
s 1 2 3 4 
Fig. 2. Expression of the human glutaredoxin in E. coli. Total bacterial lysate proteins were resolved by SDS/PAGE and stained with Coomassie 
blue (panel A) or analyzed by immunoblotting (panel B). Lane S, Pharmacia low molecular weight protein standards (14000~94000). Lane 1, control 
E. coli BL21(DE3). Lane 2, cells transformed with the PET-3d vector and induced with IPTG. Lane 3, cells transformed with the PET-grx vector 
and induced with IPTG. Lane 4, purified native human glutaredoxin (0.5 pg). 
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15°C. Excitation of fluorescence was at 230 nm and emission spectra 
from 250 to 400 nm were recorded. Emission at 310 nm was used to 
follow oxido-reductions. A preparation of 66 ,uM recombinant human 
Grx was reduced by incubation with 1 mM DTT for 15 min at 37°C 
or oxidized by addition of 100pM GSSG. The samples for fluorescence 
measurements contained 3.3 PM concentration of human glutaredoxin 
in 2 ml of N,-equilibrated 0.1 M potassium phosphate pH 7.0, 1 mM 
EDTA buffer. Denaturation of glutaredoxin was achieved by incuba- 
tion in the above buffer with 6 M guanidine hydrochloride. 
3. Results and discussion 
3.1. Construction of human glutaredoxin expression vector 
Two NcoI sites were introduced by PCR, using mutagenic 
primers (see section 2) in the cDNA encoding human glutare- 
doxin [8]: one at the translation initiation codon region and the 
other after the stop codon. The amplified DNA, which had the 
expected size (343 bp), was digested with NcoI, gel-purified and 
cloned in the expression vector PET-3d under control of a T7 
promotor. 
E. coli BL21(DE3) competent cells were transformed with the 
constructed expression vector PET-grx and purified plasmid 
DNA was sequenced using T7 and T3 promotor primers and 
two internal primers. The full nucleotide sequence of the insert 
was obtained (343 bp). The insert was in the right orientation 
for expression and its sequence was in complete agreement with 
the cDNA sequence encoding human glutaredoxin, except for 
the two new NcoI sites that we introduced for direct cloning in 
PET-3d vector (Fig. 1). 
3.2. Expression of recombinant human glutaredoxin 
The expression of recombinant human glutaredoxin in trans- 
formed bacterial culture, was induced by the addition of IPTG 
for 3.5 h. After induction, an aliquot of the bacterial culture (0.5 
ml) was centrifuged, resuspended in loading buffer and total 
cellular proteins were separated by SDS-PAGE (Phast gel ho- 
mogeneous 20) and stained with Coomassie blue. Induction 
with IPTG resulted in the appearance of a prominent protein 
which migrated at the same position as purified glutaredoxin 
from human placenta (12 kDa); it was not present in E. coli 
BL21(DE3) or transformed bacteria with the control plasmid 
PET-3d and induced with IPTG (Fig. 2A). The overexpression 
of recombinant human Grx was also verified by immunoblot- 
ting analysis using affinity-purified goat antibodies against glu- 
taredoxin from human placenta (Fig. 2B). 
Table 1 
Purification of recombinant human glutaredoxin from 10 g of E. coli 
BL21(DE3)/PET/grx cells 
Steps Protein Total activity Specific ac- Yield 
tivity 
(mg) (W Umg) (%) 
Extract 600 23,870 39 100 
Ammonium sulfate 
precipitation 468 19,750 42 83 
DEAE-Sephacel 115 14,375 125 60 
G-50 Sephadex 48 13,246 216 55 
CM-Sepharose 30 12,000 400 50 
(29)* 
(0.7)** 
*DHA reductase activity. 
**Ribonucleotide reductase activity (nmol dCDP130 min). 
71 
A) S 1 2 3 4 5 6 
B) S 1 2 3 5 6 
Fig. 3. Purification of recombinant human glutaredoxin. Samples of 
protein from the different steps were resolved by SDS-PAGE and 
stained with Coomassie blue (panel A) or analyzed by immunoblotting 
(panel B). Lane S, Pharmacia low molecular weight protein standards 
(14,000-94,000). Lane 1, 10 pg of cell extract. Lane 2, 10 pg of ammo- 
nium sulfate precipitate. Lane 3, 1 pg of DEAE-Sephacel chromatogra- 
phy pool. Lane 4, lpg of G-50 Sephadex chromatography pool. Lane 
5,0.5 pg of CM-Sepharose chromatography pool. Lane 6,0.5 pg of E. 
coli glutaredoxin. 
3.3. PuQication and characterization of recombinant human 
glutaredoxin 
The recombinant glutaredoxin was purified to homogeneity 
by ammonium sulphate precipitation, cation-exchange, gel fil- 
tration and anion exchange column chromatography steps as 
described in section 2. The procedure was similar to that used 
in the purification of glutaredoxin from human placenta [8] but 
we excluded the first CM-Sepharose chromatography for re- 
duced Grx, using only the second one for oxidized Grx. 
Samples from different steps in the purification were ana- 
lyzed by SDS-PAGE (phast gel homogeneous 20) and im- 
munoblotting (Fig. 3A and 3B). A single band of 12 kDa was 
detected after the CM-Sepharose chromatography, showing 
strong reaction with antibodies against human glutaredoxin. 
These antibodies did not cross-react with either E. coli Grxl 
(Fig. 3) or Grx2 or Grx3 (data not shown). 
The results of the purification of the recombinant human 
12 
glutaredoxin are summerized in Table 1. The purified protein 
(30 mg) was obtained in 50% yield and has a specific activity 
of 400 U/mg with HED and 29 U/mg with DHA. It also showed 
activity as hydrogen donor for heterologous mouse ribonucleo- 
tide reductase comparable to that of the protein purified from 
human placenta [8]. 
The three different assayed activities with the recombinant 
glutaredoxin gave the same values as those of glutaredoxin 
from human placenta [8]. Thus, the expression system used 
successfully produced large amounts of fully active human glu- 
taredoxin. Peptide sequencing showed absence of Met residue 
at the N-terminal (data not shown). 
Isoelectric focusing analysis of the native and recombinant 
human glutaredoxin revealed that the p1 values for the oxidized 
and reduced forms are the same in both proteins: 9.0 in its 
HED-oxidized state and 7.3 in its DTT-reduced form (Fig. 4). 
We have analyzed the fluorescence of human glutaredoxin 
in their native oxidized and reduced states as well as in their 
denatured forms using 6 M guanidine-HCl. Fluorescence emis- 
sion spectra of human Grx, adjusting the excitation wavelength 
to 230 nm, showed a peak at 310 nm but not at 350 nm (data 
not shown). This is consistent with the amino acid composition 
of the protein [8] which has two tyrosine residues (one at the 
active site) but no tryptophan residue which gives fluorescence 
at 350 nm. Fully reduced human glutaredoxin had higher lluo- 
rescence emission than that of the GSSG-oxidized form and 
this difference between non-denatured oxidized and reduced 
PI 
9.30 - 
8.65 - 
a.45 - 
8.15 - 
7.35 - 
6.85 - 
6.55 - 
5.85 - 
5.20 - 
4.55 - 
3.50 - 
Fig. 4. Isoelectric focusing of human glutaredoxin. Purified recombi- 
nant and native proteins were subjected to IEF in the range of pH 3 10 
and silver stained. Lanel, Pharmacia pI standards. Lane 2, 0.25 fig of 
native human glutaredoxin treated with 2 mM DTT for 15 min at 37°C. 
Lane 3, 0.25 pg of reduced native human glutaredoxin treated with IO 
mM HED for 30 min at room temperature. Lane 4, 0.25 pg of recom- 
binant human glutaredoxin treated with 2 mM DTT for I5 min at 37°C. 
Lane 5, 0.25 pg of reduced recombinant human glutaredoxin treated 
with IO mM HED for 30 min at room temperature. 
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Fig. 5. Relative tyrosine fluorescence of oxidized and reduced human 
glutaredoxin (3.3 PM). To the reduced form, IOOpM GSSG was added 
after 50 s. Solide line corresponds to non denatured protein and dashed 
line to denatured protein. The emission wavelength was 310 nm. 
states was higher in the denatured protein (Fig. 5). In human 
Grx, this effect was observed at 230 nm of excitation, suggesting 
disulfide quenching of the tyrosine residue at the active site 
(Tysr2”) in oxidized glutaredoxin by mechanisms similar to that 
for tryptophan fluorescence in E. coli thioredoxin [26] or calf 
thymus protein disulfide isomerase [27]. The structure of E. coli 
Grx has been determined [28-301 and the active site disulfide 
is located in a loop after the first P-strand (/I]) and is followed 
by a long a-helix (al). The structure of human Grx is unknown 
but a similar localization of the active site was predicted [8]. 
3.4. Esprrssion, pur$cution and characterization of 
recombinant human glutaredoxin mutant (CL,.? to Ser) 
The procedure was the same as described for expression of 
human Grx wild type but changing the mutagenic primer at the 
5’ end. The full nucleotide sequence of the insert was obtained 
and the mutation at the right position was confirmed. The rest 
of the sequence was exactly the same as that obtained for the 
insert of the human Grx expression vector. The purification 
procedure was identical to that described for the purification 
of recombinant wild type Grx and peptide sequencing con- 
firmed the Ser residue and no N-terminal Met-residue (data not 
shown). The pure mutant protein had the same properties and 
specific activity as the wild type protein but showed much lower 
tendency to form dimers. If this extra Cys residue, not present 
in other mammalian glutaredoxins, plays a special role in 
human glutaredoxinit will be subject to further studies. 
The expression system described in this paper will be useful1 
for production of recombinant protein to investigate the molec- 
ular properties of glutaredoxin by multidimensional NMR or 
X-ray crystallography and site-directed mutagenesis. 
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